Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-19T04:00:21.482Z Has data issue: false hasContentIssue false
  • English
  • Français

Update on Dopamine Agonists in Parkinson's Disease: “Beyond Bromocriptine”

Published online by Cambridge University Press:  05 January 2016

Anthony E. Lang
Anthony E. Lang*
Affiliation:
Movement Disorders Clinic, Toronto Western Hospital, Toronto
*
25 Leonard Avenue, Suite 301, Toronto, Ontario, Canada M5T 2R2
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Since the initiation of bromocriptine therapy for Parkinson's disease several newer dopamine agonists have been developed. Pergolide has reached the stage of Phase 3 clinical trials and will probably be available for general use sometime in the foreseeable future. Lisuride shows most promise in its parenteral form for infusion therapy of patients with severe fluctuations. Mesulergine, another ergot-derivative and ciladopa, a new non-ergot agonist, have been withdrawn from further clinical use due to tumorogenesis in rats. It is questionable how applicable these findings are to the use of the drugs in elderly humans with parkinsonism. Recently a small number of drugs have been found to have postsynaptic dopamine agonist properties only in the setting of denervated supersensitive dopamine receptors. These agents may be particularly effective in the early treatment of patients with Parkinson's disease. This paper will review a number of the dopamine agonists which have been developed since the introduction of bromocriptine therapy. Several of these have shown beneficial effects in early clinical trials while others show promise in preclinical studies of animal models of parkinsonism.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue S3 , August 1987 , pp. 474 - 482
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

REFERENCES

1.Schwab, RS, Amador, LV, Lettvin, JY. Apomorphine in Parkin- son’s disease. Trans Am Neurol Assoc 1951; 76: 251–253Google Scholar
2.Duby, SE, Cotzias, GC, Papavasiliou, PS, Lawrence, WA. Injected apomorphine and orally administered levodopa in parkinsonism. Arch Neurol 1972; 27: 474–480.CrossRefGoogle ScholarPubMed
3.Cotzias, GC, Papavasiliou, PS, Tolosa, ES, et al. Treatment of Parkinson’s disease with apomorphines. Possible role of growth hormones. New Engl J Med 1976; 294: 567–572.CrossRefGoogle Scholar
4.Corrodi, H, Fuxe, K, Ungerstedt, U.Evidence for a new type of dopamine receptor stimulating agent. J Pharm Pharmacol 1971 ; 23: 989–991.CrossRefGoogle ScholarPubMed
5.Teychenne, PF, Pfeiffer, RF, Bern, SM, Calne, DB.Experiences with a new ergoline (CF 25-397) in parkinsonism. Neurology 1977; 27: 1140–1143.CrossRefGoogle ScholarPubMed
6.Rinne, UK.Dopamine agonists in the treatment of Parkinson's disease. Adv Neurol 1983; 37: 141–150.Google ScholarPubMed
7.Setler, PE, Sarau, HM, Kirkle, CL, Saunders, HL.The central effects of novel dopamine agonists. Eur J Pharmacol 1978; 50: 419–430.CrossRefGoogle Scholar
8.Euvrard, C, Ferland, L, DiPaolo, T, et al. Activity of two new dopaminergic agonists at the striatal and anterior pituitary levels. Neuropharmacology 1980; 19: 379–386.CrossRefGoogle ScholarPubMed
9.Tsuruta, K, Frey, EA, Grewe, CW, et al. Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor. Nature 1981 ; 292: 463–465.CrossRefGoogle ScholarPubMed
10.Kebabian, JW, Beaulieu, M, Itoh, Y.Pharmacological and biochemi- cal evidence for the existence of two categories of dopamine receptors. Can J Neurol Sci 1984; 11: 114–117.CrossRefGoogle Scholar
11.Lieberman, A, Goldstein, M, Leibowitz, M, et al. Treatment of advanced Parkinson’s disease with pergolide. Neurology (NY) 1981; 131: 675–682.CrossRefGoogle Scholar
12.Lang, AE, Quinn, N, Brincat, S, et al. Pergolide in late-stage Parkin- son disease. Ann Neurol 1982; 12: 243–247.CrossRefGoogle Scholar
13.Tanner, CM, Goetz, CG, Glantz, RH, et al. Pergolide mesylate and idiopathic Parkinsondisease. Neurology(NY) 1982;32:1175–1179.Google Scholar
14.Jankovic, J.Controlled trial of pergolide mesylate in Parkinson’s disease and progressive supranuclear palsy. Neurology 1983; 33: 505–507.CrossRefGoogle ScholarPubMed
15.Sage, JI, Duvoisin, RC.Pergolide therapy in Parkinson's disease: A double-blind placebo-controlled study. Clin Neuropharmacol 1985; 8: 260–265.CrossRefGoogle ScholarPubMed
16.Diamond, SG, Markham, CH, Treciokas, LJ. Double-blind trial of pergolide for Parkinson’s disease. Neurology 1985; 35: 291–295.CrossRefGoogle ScholarPubMed
17.Jankovic, J, Orman, J.Parallel double-blind study of pergolide in Parkinson disease. Presented at the 8th International Symposium on Parkinson’s Disease, New York City, June 1985, abstract 116.Google Scholar
18.Olanow, CW, Alberts, MJ.A double blind controlled study of pergolide mesylate vs. placebo in the treatment of Parkinson’s disease. Presented at the 8th International Symposium on Parkinson’s Disease, New York City, June 1985, abstract 117.Google Scholar
19.Kurlan, R, Miller, C, Levy, R, et al. Long-term experience with pergolide therapy of advanced parkinsonism. Neurology 1985; 35: 738–742.CrossRefGoogle ScholarPubMed
20.Lieberman, AN, Goldstein, M, Liebowitz, M, et al. Long-term treatment with pergolide: Decreased efficacy with time. Neurology 1984; 34: 223–226.Google ScholarPubMed
21.Sage, JI, Duvoisin, RC.Long-term efficacy of pergolide in patients with Parkinson's disease. Clin Neurolpharmacol 1986;9:160–164.CrossRefGoogle ScholarPubMed
22.Jankovic, J.Long-term study of pergolide in Parkinson’s disease. Neurology 1985; 35: 296–299.CrossRefGoogle ScholarPubMed
23.Goetz, CG, Tanner, CM, Glantz, RH, Klawans, HL.Chronic ago- nist therapy for Parkinson’s disease: A five year study of bromocriptine and pergolide. Neurology 1985; 35: 749–751.CrossRefGoogle Scholar
24.Lieberman, AN, Neophytides, A, Liebowitz, M, et al. Comparative efficacy of pergolide and bromocriptine in patient's with Parkinson’s disease. Adv Neurol 1983; 37: 95–108.Google Scholar
25.LeWitt, PA, Ward, CD, Larsen, TA, et al. Comparisons of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983; 33: 1109–1114.CrossRefGoogle ScholarPubMed
26.Tanner, CM, Goetz, CG, Glantz, RH, Klawans, HL. Pergolide mesylate: Four years experience in Parkinson’s disease. Presented at the 8th International Symposium on Parkinson’s disease. New York City, June 1985, abstract 118.Google Scholar
27.Leibowitz, M, Lieberman, AN, Neophytides, A, et al. The effects of pergolide on the cardiovascular system of 40 patients with Parkinson’s disease. Adv Neurol 1983; 37: 121–130.Google ScholarPubMed
28.Tanner, CM, Chablani, R, Goetz, CG, Klawans, HL. Pergolide mesylate. Lack of cardiac toxicity in patients with cardiac disease. Neurology 1985; 35: 918–921.CrossRefGoogle ScholarPubMed
29.Kurlan, R, Miller, C, Knapp, R, et al. Double-blind assessment of potential pergolide-induced cardiotoxicity. Neurology 1986; 36: 993–995.CrossRefGoogle ScholarPubMed
30.Mear, J-Y, Barroche, G, DeSmet, Y, et al. Pergolide in the treatment of Parkinson’s disease. Neurology 1984; 34: 983–986.CrossRefGoogle ScholarPubMed
31.Goldstein, M, Lieberman, A, Meller, E. A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa. TIPS 1985; 6: 436–437.Google Scholar
32.Waddington, JL. Bromocriptine, selective D2 dopamine receptor agonists and Dl dopaminergic tone. TIPS 1986; 7: 223–224.Google Scholar
33.Robertson, HA, Robertson, GS. The antiparkinson action of bromocriptine in combination with levodopa. TIPS 1986; 7: 224–225.Google Scholar
34.Kehr, W. Effect of lisuride and otherergot derivatives on monoaminergic mechanisms in rat brain. Eur J Pharmacol 1976; 41: 261–273.CrossRefGoogle Scholar
35.Burns, RS, Gopinathan, G, Humpel, M, et al. The pharmacokinetics of lisuride in parkinsonian patients. Neurology 1981; 31: 49–50.Google Scholar
36.Suchy, I, Horowski, R. Use of ergot derivative lisuride in Parkinson’s disease. Adv Neurol 1984; 40: 515–521.Google ScholarPubMed
37.Martignoni, E, Suchy, I, Pacchetti, C, et al. Lisuride in Parkinson’s disease: Naive and long-term treatment. Curr Ther Res 1986; 39: 696–708.Google Scholar
38.Giovannini, P, Scigliano, G, Suchy, I, Caraceni, T. Long-term treatment of Parkinson’s disease with lisuride. Presented at the 8th International Symposium on Parkinson’s Disease, New York, June 1985, abstract P90.Google Scholar
39.Rinne, UK. New ergot derivatives in the treatment of Parkinson’s disease. In: Calne, DB, Horowski, R, McDonald, RJ, Wuttke, W, eds. Lisuride and other dopamine agonists. New York, Raven Press, 1983; 431–442.Google Scholar
40.Agnoli, A, Suggieri, S, Baldassarre, M, et al. Dopaminergic ergots in parkinsonism. In: Calne, DB, Horowski, R, McDonald, RJ, Wuttke, W, eds. Lisuride and other dopamine agonists. New York, Raven Press, 1983: 407–418.Google Scholar
41.Lieberman, AN, Gopinathan, G, Neophytides, A. Bromocriptine and lisuride in Parkinson disease. Ann Neurol 1983; 13: 44–47.CrossRefGoogle ScholarPubMed
42.Caraceni, T, Giovannini, P, Parati, E, et al. Bromocriptine and lisuride in Parkinson’s disease. Adv Neurol 1984; 40: 531–536.Google ScholarPubMed
43.LeWitt, PA, Gopinathan, G, Ward, CD, et al. Lisuride versus bromocriptine treatment in Parkinson disease: A double-blind study. Neurology (NY) 1982; 32: 69–72.CrossRefGoogle ScholarPubMed
44.Schacter, M, Sheehy, MP, Parkes, JD, Marsden, CD. Lisuride in the treatment of parkinsonism. Acta Neurol Scandinav 1980; 62: 382–385.CrossRefGoogle Scholar
45.LeWitt, PA, Calne, DB. Experience with dopamine agonists in Parkinson’s disease and related disorders. In: Calne, DB, Horowski, R, McDonald, RJ, Wuttke, W, eds. Lisuride and other dopamine agonists. New York, Raven Press, 1983: 473–480.Google Scholar
46.Lieberman, AN, Gopanathan, G, Neophytides, A, et al. Pergolide and lisuride in advanced Parkinson's disease. Adv Neurol 1984; 40: 503–507.Google ScholarPubMed
47.Birkmayer, W, Riederer, P. Effects of lisuride on motor function, psychomotor activity and psychic behaviour in Parkinson’s disease. In: Calne, DB, Horowski, R, McDonald, RJ, Wuttke, W, eds. Lisuride and other dopamine agonists. New York, Raven Press, 1983: 453–461.Google Scholar
48.Meneghetti, G, Braceo, F, Giometto, B, et al. Therapeutic effect of lisuride in advanced Parkinson’s disease. Eur Neurol 1986; 25: 74–80.CrossRefGoogle ScholarPubMed
49.Lieberman, AN, Goldstein, M, Liebowitz, M, et al. Lisuride combined with levodopa in advanced Parkinson disease. Neurology (NY) 1981; 31: 1466–1469.CrossRefGoogle ScholarPubMed
50.Micheli, F, Fernandez-Pardl, MM, Leiguarda, RC. Beneficial effects of lisuride in Meige disease. Neurology (NY) 1982; 32: 432–434.CrossRefGoogle ScholarPubMed
51.Nutt, JG, Hammerstad, JP, Carter, JH.Dejarmo, PL.Lisuride treat-ment of focal dystonias. Neurology 1985; 35: 1242–1243.CrossRefGoogle Scholar
52.Quinn, NP, Lang, AE, Sheehy, MP, Marsden, CD.Lisuride in dystonias. Neurology 1985; 35: 766–769.CrossRefGoogle Scholar
53.Obeso, JA, Rothwell, JC, Quinn, NP, et al. Cortical reflex myoclo-nus response to intravenous lisuride. Clin Neuropharmacol 1983; 6: 231–240.CrossRefGoogle Scholar
54.Markstein, R.Mesulergine and its 1,20-N,N-bidemethylated metab-olite interact directly with Dl and D2-receptors. Eur J Pharmacol 1983; 95: 101–107.CrossRefGoogle Scholar
55.Pfeiffer, RF.The pharmacology of mesulergine. Clin Neurophar-macol 1985; 8: 64–72.CrossRefGoogle ScholarPubMed
56.Lataste, X.The history and pharmacology of dopamine agonists. Can J Neurol Sci 1984; 11: 118–123.CrossRefGoogle ScholarPubMed
57.Jankovic, J, Orman, J, Jansson, B.Placebo controlled study of mesulergine in Parkinson’s disease. Neurology 1985; 3: 161–165.CrossRefGoogle Scholar
58.Burton, K, Larsen, A, Robinson, G, et al. Parkinson’s disease: A comparison of mesulergine and bromocriptine. Neurology 1985; 35: 1205–1208.CrossRefGoogle ScholarPubMed
59.Rascol, A, Montastruc, JL, Rascol, O, Senard, JM.Mesulergine (CU 32–085) in the treatment of Parkinson’s disease. Clin Neuropharmacol 1986; 9: 146–152.CrossRefGoogle ScholarPubMed
60.Dupont, E, Mikkelsen, B, Jakobsen, J.Mesulergine in early Parkinson’s disease: a double blind controlled trial. J Neurol Neuros urg Psychiatry 1986; 49: 390–395.CrossRefGoogle ScholarPubMed
61.Teravainen, H, Huttenen, J, Hietanen, M.Initial treatment of par-kinsonism with 8-alpha-amino-ergoline. Neurology 1985; 35:83–87.CrossRefGoogle ScholarPubMed
63.Bonnet, AM, Esteguy, M, Guimaraes, A, et al. Low-dose CU-32-085(mesulergine) in previously untreated Parkinson’s disease. Neurology 1984; 34: 1127–1128.CrossRefGoogle ScholarPubMed
64.Schneider, E, Hubener, K, Fischer, PA.Treatment of Parkinson’s disease with 8-alpha-amino-ergoline, CU 32–085. Neurology 1983; 33: 468–472.CrossRefGoogle ScholarPubMed
65.Jellinger, K.Adjuvant treatment of Parkinson’s disease with dopa-mine agonists: Open trial with bromocriptine and CU 32–085. J Neurol 1982; 227: 75–88.CrossRefGoogle Scholar
66.Corsini, GU, Horowski, R, Rainer, E, Delzompo, M.Treatment of Parkinson’s disease with a dopamine partial agonist. Clin Neuropharmacol 1984: 7 (suppl 1): 950–951.CrossRefGoogle Scholar
67.Pfeiffer, RF, Wilken, K, Glaeske, C.Mesulergine (CU 32–085) in the treatment of Parkinson’s disease. Ann Neurol 1985; 17: 334–336.CrossRefGoogle ScholarPubMed
68.Pfeiffer, RF, Wilken, K, Glaeske, C.Longterm efficacy of mesuler-gine (CU 32–085) in parkinsonism. Neurology 1984; 34: (suppl 1 ): 159.Google Scholar
69.Hoehn, MM.Mesulergine treatment of Parkinson’s disease: An 18-month followup. Ann Neurol 1984; 16: 128.Google Scholar
70.Baas, H, Schneider, E, Fischer, P-A, Japp, G.Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism. J Neurol Transmission 1985; 64: 45–54.CrossRefGoogle ScholarPubMed
71.Schneider, E, Baas, H, Fischer, P-A, Japp, G.Three-year observa-tion of mesulergine (CU-32–085) in advanced and newly treated parkinsonism. J Neurol 1985; 232: 24–28.CrossRefGoogle Scholar
72.Lieberman, AN, Gopinathan, G, Neophytides, A.Efficacy of per-golide and mesulergine. Eur Neurol 1986; 25: 86–90.CrossRefGoogle ScholarPubMed
73.Roller, WC, Fields, JZ, Gordon, JH, Perlow, MJ.Evaluation of ciladopa hydrochloride as a potential anti-parkinsonian drug. Neuropharm 1986; 25: 973–979.Google Scholar
74.Klawans, HL, Goetz, C, Nauseda, PA, Weiner, WJ.Levodopa-induced dopamine receptor hypersensitivity. Ann Neurol 1977; 2: 125–129.CrossRefGoogle Scholar
75.Nauseda, PA, Weiner, WJ, Kanapa, DJ, Klawans, HL.Bromocrip-tine-induced behavioural hypersensitivity: Implications for therapy of parkinsonism. Neurology 1978; 28: 1183–1188.CrossRefGoogle Scholar
76.Klawans, HL, Margolin, DI.Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Arch Gen Psychiat 1975; 32: 725–732.CrossRefGoogle ScholarPubMed
77.Snider, SR.Effect of ciladopa in Sinemet-treated parkinsonian patients. Neurology 1985; 35 (suppl1): 203.Google Scholar
78.Lieberman, AN, Goldstein, M, Gopinathan, G, Neophytides, A, et al. The use of of the partial dopamine agonist of ciladopa in advanced Parkinson’s disease. Neurology 1985; 35 (suppl 1): 203.Google Scholar
79.Weiner, WJ, Berger, JR.Effect of ciladopa on Parkinson’s disease: A preliminary report. In: Yahr, MD and Bergmann, KJ, eds Adv Neurol 1986; 45: 583–586.Google Scholar
80.Weiner, WJ, Factor, SA, Sanchez-Ramos, J, Berger, J.A double-blind evaluation of ciladopa in Parkinson’s disease (submitted for publication).Google Scholar
81.Dorow, R, Breitkopf, M, Graf, KJ, Horowski, R.Neuroendocrine effects of lisuride and its 9,10-dihydrogenated analogue in healthy volunteers. In: Calne, DB, Horowski, R, Mcdonald, RJ, Wuttke, W, eds. Lisuride and other dopamine agonists. New York, Raven Press, 1983; 161–174.Google Scholar
82.Bassi, S, Albizzati, MG, Corsini, U, et al. Therapeutic experience with transdihydrolisuride in Huntington’s disease. Neurology 1986; 36: 984–986.CrossRefGoogle ScholarPubMed
83.Corsini, GU, Bonuccelli, U, Rainer, E, Delzempo, M.Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients. J Neural Trans 1985; 64: 105–111.CrossRefGoogle ScholarPubMed
84.Brucke, T, Danielczyj, W, Simany, M, Reider, P.First clinical results with the partial dopamine agonist tersuride: Study in 15 parkinsonian patients. Presented at the 8th International Symposium on Parkinson’s Disease, New York, June 1985. Abstract 109.Google Scholar
85.Suchy, I, Rinne, UK, Wachtel, H.Time course and dose response after the partial dopamine-agonist terguride in patients with Parkinson’s disease. Presented at the 8th International Symposium on Parkinson’s Disease, New York, June 1985. Abstract 110.Google Scholar
85a.Critchley, P, Parkes, D.Transdihydrolisuride in Parkinsonism. Clin Neuropharmacol 1987; 10: 57–64.CrossRefGoogle ScholarPubMed
86.Stoessl, AJ, Mak, E, Calne, DB. ( + )-4-propyl-9-hydroxynaphthox- azine (PHNO), a new dopaminominmetic in treatment of parkinsonism. Lancet 1985; 2: 130–1331.Google ScholarPubMed
87.Weiner, WJ, Sanchez-Ramos, J, Factor, SA, Hefti, F.The efficacy of 4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson’s disease. Neurology 1987; 37 (Suppl 1): 276.Google Scholar
88.Jaton, AL, Giger, RKA, Vigouret, JN, et al. Pharmacological pro-file of the abeorphine 201–678, a potent orally active and lasting dopamine agonist. Life Sci 1986; 38: 155–163.CrossRefGoogle Scholar
89.Birbamer, J, Ransmayr, G, Poewe, W, Gestenbrand, F.Therapeutic experience with an abeorphine-derivative in Parkinson’s disease. Presented at the 8th International Symposium on Parkinson’s Disease. New York City, June 1985. Abstract 105.Google Scholar
90.Horn, AS, Tepper, P, Kebabian, JW, Beart, PM. N-0434, a very potent and specific new D2 dopamine receptor agonist. Eur J Pharmacol 1984; 99: 125CrossRefGoogle Scholar
91.Van der Weide, J, de Vries, JB, Tepper, PG, Horn, AS.Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734. Eur J Pharmacol 1986; 125: 273–282.CrossRefGoogle ScholarPubMed
92.Anden, N-E, Nilsson, H, Ros, H, Thornstrom, U.Effects of B-HT 920 and B-HT 933 on dopamine and noradrenalin autoreceptors in the rat brain. Acta Pharmacol Toxicol 1983; 52: 51–56.CrossRefGoogle ScholarPubMed
93.Hinzen, D, Hornykiewicz, O, Kobinger, W, et al. The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson’s disease: A novel approach to treatment. Eur J Pharmacol 1986; 131: 75–86.CrossRefGoogle ScholarPubMed
94.Hjorth, S, Carlsson, A, Clard, D, et al. 3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci 1981; 28: 1225–1238.CrossRefGoogle ScholarPubMed
95.Hjorth, , Carlsson, A, Clark, D, et al. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmalology 1983; 81: 89–99.CrossRefGoogle ScholarPubMed
96.Clark, D, Hjorth, S, Carlsson, A.( + )- and (-)-3PPP exhibit different intrinsic activity on striatal dopamine autoreceptors controlling dopamine synthesis. Eur J Pharmacol 1984; 106: 185–189.CrossRefGoogle ScholarPubMed
97.Clark, D, Engberg, G, Pileblad, E, et al. An electrophysiological analysis of the effects of the enantiomers of 3-PPP on the nigros-triatal dopamine system. Naunyn-Schmiedebergs Arch Phar-mac 1985; 329: 344–354.CrossRefGoogle ScholarPubMed
98.Arnt, J, Bogeso, KP, Christensen, AV, Hyttel, J, et al. Dopamine receptor agonistic and antagonistic effects of 3-PPP ebabtuin-ers, Psychopharmacology 1983; 81: 199–207.CrossRefGoogle Scholar
99.Nomoto, M, Jenner, P, Marsden, CD.Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-related marmoset. Eur J Pharmacol 1986; 121: 123–128.CrossRefGoogle Scholar
100.Rinne, UK.Brain neurotransmitter receptors in Parkinson’s disease. In: Marsden, CD, Fahn, S, eds. Movement Disorders. London, Butterworth’s, 1982: 59–74.Google Scholar
101.Klawans, HL.Individual manifestations of Parkinson’s disease after ten or more years of levodopa. Movement Disorders 1986; 1: 187–192.CrossRefGoogle ScholarPubMed
102.Lewin, R.Clinical trial for Parkinson’s disease? Science 1985; 230: 527–528.CrossRefGoogle ScholarPubMed